Gilead Sciences | GILD - Current Liabilities

Stock Price
141.65
Daily Change
-0.30 -0.21%
Monthly
19.74%
Yearly
43.98%
Q1 Forecast
137.58

Gilead Sciences reported $12.3B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
GlaxoSmithKline GBP 21.33B 956M Sep/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.68B 109M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025